CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T and antibody therapeutics.


Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the United States. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-Claudin18.2-T for gastric and pancreatic cancer, CAR-GPC3-T for hepatocellular carcinoma (HCC) and squamous lung cancer and CAR-EGFR/EGFRvIII-T for glioblastoma. CARsgen also has ongoing clinical programs with a fully human CAR-BCMA-T for multiple myeloma and a humanized CAR-CD19-T for leukemia.


CARsgen’s proprietary antibody platform enables the development of therapeutic antibodies. Its leading humanized monoclonal antibody targeting Claudin18.2 has obtained IND approval from the NMPA.